CIK 0000879407 · Large accelerated filer
ARROWHEAD PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- ARWR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 460408024
- Phone
- 626-696-4702
- Business address
- 177 E COLORADO BLVD, SUITE 700, PASADENA, CA, 91105
- Former names
- ARROWHEAD RESEARCH CORP, INTERACTIVE GROUP INC, INTERACTIVE INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,186,600
- in 2 filings
Net −$1,186,600. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-12-29 | Myszkowski Kenneth Allen Chief Financial Officer | Sale | −30,625 | $40.00 | $1.2M | 336,704 |
| 2022-12-21 | O'Brien Patrick General Counsel | Option exercise | +32,000 | $6.15 | $197K | 380,875 |
| 2022-12-21 | O'Brien Patrick General Counsel | Option exercise · Stock Option (right to buy Common Stock) | −32,000 | 0 | ||
| 2022-12-20 | Anzalone Christopher Richard Chief Executive Officer | Grant or award | +234,025 | 3,720,714 | ||
| 2022-12-16 | Anzalone Christopher Richard Chief Executive Officer | Grant or award | +18,375 | 3,486,689 | ||
| 2022-11-21 | San Martin Javier Chief Medical Officer | Sale | −19,300 | $29.98 | $579K | 91,700 |
| 2022-11-21 | San Martin Javier Chief Medical Officer | Sale | −200 | $30.62 | $6K | 91,500 |
| 2022-09-27 | Anzalone Christopher Richard Chief Executive Officer | Option exercise | −39,082 | $30.77 | $1.2M | 3,469,856 |
| 2022-09-27 | Anzalone Christopher Richard Chief Executive Officer | Option exercise | −1,542 | $31.21 | $48K | 3,468,314 |
| 2022-07-08 | Anzalone Christopher Richard Chief Executive Officer | Returned to the company | −551,197 | 3,508,938 | ||
| 2022-07-07 | Anzalone Christopher Richard Chief Executive Officer | Option exercise | +2,501 | $14.54 | $36K | 4,060,135 |
| 2022-07-07 | Anzalone Christopher Richard Chief Executive Officer | Option exercise · Stock Option (right to buy Common Stock) | −2,501 | 612,532 | ||
| 2022-02-11 | Anzalone Christopher Richard Chief Executive Officer | Option exercise | +146,388 | $5.19 | $760K | 4,204,022 |
| 2022-02-11 | Anzalone Christopher Richard Chief Executive Officer | Sale | −40,853 | $53.11 | $2.2M | 4,163,169 |
| 2022-02-11 | Anzalone Christopher Richard Chief Executive Officer | Sale | −42,153 | $52.28 | $2.2M | 4,121,016 |
| 2022-02-11 | Anzalone Christopher Richard Chief Executive Officer | Sale | −61,482 | $50.90 | $3.1M | 4,059,534 |
| 2022-02-11 | Anzalone Christopher Richard Chief Executive Officer | Sale | −1,900 | $50.51 | $96K | 4,057,634 |
| 2022-02-11 | Anzalone Christopher Richard Chief Executive Officer | Option exercise · Stock Option (right to buy Common Stock) | −146,388 | 615,033 | ||
| 2022-01-07 | Anzalone Christopher Richard Chief Executive Officer | Option exercise | +11,806 | $5.19 | $61K | 4,057,634 |
| 2022-01-07 | Anzalone Christopher Richard Chief Executive Officer | Option exercise · Stock Option (right to buy Common Stock) | −11,806 | 761,421 |
Page 14 of 38 · 752 trades